Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen Delaney

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Healthcare Financial Management : Journal of the Healthcare Financial Management Association|December 16, 2015
Using business analytics to improve outcomesJose Rivera, Stephen Delaney
Toxicology and Applied Pharmacology|November 11, 2017
Temporal cytokine and lymphoid responses to an inhaled TLR7 antedrug agonist in the cynomolgus monkey demonstrates potential safety and tolerability of this approachJohn Bell, Mike Dymond, Mark Biffen, et al.
Frontiers in Allergy|May 15, 2025
T2 cytokine-driven alarmin and antiviral responses in asthma: insights into immune modulation and the role of IL-4Rα targetingJelena Pesic, Juan José Nieto-Fontarigo, Katerina Pardali, et al.
BMJ Open Respiratory Research|March 3, 2016
Tolerability in man following inhalation dosing of the selective TLR7 agonist, AZD8848Stephen Delaney, Mark Biffen, Justine Maltby, et al.
Plos One|December 17, 2020
Optimised generation of iPSC-derived macrophages and dendritic cells that are functionally and transcriptionally similar to their primary counterpartsSusan Monkley, Jayendra Kumar Krishnaswamy, Melker Göransson, et al.
Clinical Pharmacology and Therapeutics|November 15, 2017
First-in-Human Study With the Inhaled TLR9 Oligonucleotide Agonist AZD1419 Results in Interferon Responses in the Lung, and Is Safe and Well-ToleratedSam Jackson, Albert F Candia, Stephen Delaney, et al.
Nature Structural & Molecular Biology|February 7, 2023
Quaternary glucocorticoid receptor structure highlights allosteric interdomain communicationSandra Postel, Lisa Wissler, Carina A Johansson, et al.
American Journal of Respiratory and Critical Care Medicine|August 19, 2020
A Phase 2a, Double-Blind, Placebo-controlled Randomized Trial of Inhaled TLR9 Agonist AZD1419 in AsthmaIoannis Psallidas, Vibeke Backer, Piotr Kuna, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Healthcare Financial Management : Journal of the Healthcare Financial Management Association|December 16, 2015
Using business analytics to improve outcomesJose Rivera, Stephen Delaney
Toxicology and Applied Pharmacology|November 11, 2017
Temporal cytokine and lymphoid responses to an inhaled TLR7 antedrug agonist in the cynomolgus monkey demonstrates potential safety and tolerability of this approachJohn Bell, Mike Dymond, Mark Biffen, et al.
Frontiers in Allergy|May 15, 2025
T2 cytokine-driven alarmin and antiviral responses in asthma: insights into immune modulation and the role of IL-4Rα targetingJelena Pesic, Juan José Nieto-Fontarigo, Katerina Pardali, et al.
BMJ Open Respiratory Research|March 3, 2016
Tolerability in man following inhalation dosing of the selective TLR7 agonist, AZD8848Stephen Delaney, Mark Biffen, Justine Maltby, et al.
Plos One|December 17, 2020
Optimised generation of iPSC-derived macrophages and dendritic cells that are functionally and transcriptionally similar to their primary counterpartsSusan Monkley, Jayendra Kumar Krishnaswamy, Melker Göransson, et al.
Clinical Pharmacology and Therapeutics|November 15, 2017
First-in-Human Study With the Inhaled TLR9 Oligonucleotide Agonist AZD1419 Results in Interferon Responses in the Lung, and Is Safe and Well-ToleratedSam Jackson, Albert F Candia, Stephen Delaney, et al.
Nature Structural & Molecular Biology|February 7, 2023
Quaternary glucocorticoid receptor structure highlights allosteric interdomain communicationSandra Postel, Lisa Wissler, Carina A Johansson, et al.
American Journal of Respiratory and Critical Care Medicine|August 19, 2020
A Phase 2a, Double-Blind, Placebo-controlled Randomized Trial of Inhaled TLR9 Agonist AZD1419 in AsthmaIoannis Psallidas, Vibeke Backer, Piotr Kuna, et al.
Pageof 1